PIPELINE & PRODUCT CATEGORIES
Find out more about Biocidium’s three focus areas of medical research:
ONCOLOGY
Preclinical
Phase 1
Phase 2
Phase 3
Phase 4
Indication – Melanoma, SSC, BBC | Formulation – Oral and Topical
Indication – Various | Formulation – Intravenous
ANTIFUNGALS
Preclinical
Phase 1
Phase 2
Phase 3
Phase 4
Indication – Candida auris (Antimicrobial Resistant) | Formulation – Oral and Topical
Indication – Candida albicans (Antimicrobial Resistant) | Formulation – Oral and Topical
Indication – Various | Formulation – Intravenous
ANTIBIOTICS
Gram-Positive
Preclinical
Phase 1
Phase 2
Phase 3
Phase 4
Indication – Staphylococcus aureus – methicillin resistant (MRSA) | Formulation – Oral and Topical
Indication – Enterococcus faecalis – vancomycin resistant (VRE) | Formulation – Oral and Topical
Indication – Streptocuccus pneumoniae – MDR | Formulation – Oral and Topical
Indication – Various | Formulation – Intravenous
Gram-Negative
Preclinical
Phase 1
Phase 2
Phase 3
Phase 4
Indication – Carbapenem-resistant enterobacteriaceae (CRE) | Formulation – Oral and Topical
Indication – Neisseria gonorrhoeae – DR | Formulation – Oral and Topical
Indication – Pseudomonas aeruginosa – MDR | Formulation – Oral
Indication – Shigella – DR | Formulation – Oral and Topical
DERMATOLOGY
Preclinical
Phase 1
Phase 2
Phase 3
Phase 4
Indication – Acne vulgaris | Formulation – Topical
Indication – Pruritus | Formulation – Topical